ストックスクリーナーアプリを入手
49.35
0.33%
-0.17
前日終値:
$49.52
開ける：
$49.68
24時間の取引高:
433.17K
Relative Volume:
0.55
時価総額：
$2.83B
収益：
$665.13M
当期純損益:
$64.50M
株価収益率:
43.13
EPS:
1.1442
ネットキャッシュフロー:
$185.87M
1週間 パフォーマンス:
-1.80%
1か月 パフォーマンス:
-4.17%
6か月 パフォーマンス:
+51.07%
1年 パフォーマンス:
+29.30%
1日の値動き範囲:
$49.14
$50.45
1週間の範囲:
$48.84
$50.55
52週間の値動き範囲:
$29.16
$57.65
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
名前
Supernus Pharmaceuticals Inc
セクター
電話
301-838-2500
住所
9715 KEY WEST AVENUE, ROCKVILLE, MD
SUPN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
49.35 | 2.84B | 665.13M | 64.50M | 185.87M | 1.1442 |
|
ZTS
Zoetis Inc
|
124.02 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.96 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.64 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.90 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-09 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-09-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | 再開されました | Jefferies | Buy |
| 2021-12-01 | 再開されました | Jefferies | Buy |
| 2021-04-13 | アップグレード | Jefferies | Hold → Buy |
| 2020-06-16 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | 再開されました | Jefferies | Hold |
| 2019-11-08 | ダウングレード | Berenberg | Buy → Hold |
| 2019-11-07 | ダウングレード | Stifel | Buy → Hold |
| 2019-11-06 | ダウングレード | Jefferies | Buy → Hold |
| 2018-11-12 | 繰り返されました | B. Riley FBR | Buy |
| 2018-01-18 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | アップグレード | Janney | Neutral → Buy |
| 2017-11-08 | アップグレード | Stifel | Hold → Buy |
| 2017-10-19 | 開始されました | FBR & Co. | Buy |
| 2017-09-19 | ダウングレード | Stifel | Buy → Hold |
| 2017-07-17 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | 開始されました | Janney | Neutral |
| 2017-06-01 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | アップグレード | Jefferies | Hold → Buy |
| 2015-11-05 | 繰り返されました | Northland Capital | Outperform |
| 2015-10-28 | 開始されました | Northland Capital | Outperform |
すべてを表示
Supernus Pharmaceuticals Inc (SUPN) 最新ニュース
Loss Report: Is Supernus Pharmaceuticals Inc stock forming a triangle pattern2025 Buyback Activity & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Strong results lifted Supernus Pharmaceuticals (SUPN) in Q3 - MSN
Supernus Pharmaceuticals (SUPN) Stock Analysis: Exploring A 22.67% Potential Upside - DirectorsTalk Interviews
Chart Watch: Is Supernus Pharmaceuticals Inc a stock for growth or value investorsRate Cut & Weekly Sector Rotation Insights - baoquankhu1.vn
Stifel Raises Price Target for Supernus Pharmaceuticals (SUPN) t - GuruFocus
Investment Review: Should you avoid Supernus Pharmaceuticals Inc stock right now2025 Volume Leaders & Safe Capital Growth Stock Tips - baoquankhu1.vn
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
(SUPN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Supernus to acquire depression drugmaker Sage - MSN
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
How Supernus Pharmaceuticals Inc. stock performs after earningsJuly 2025 Pullbacks & Comprehensive Market Scan Insights - Улправда
Supernus Pharmaceuticals Inc. (SUPN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cantor Fitzgerald reiterates Overweight rating on Supernus Pharmaceuticals stock By Investing.com - Investing.com UK
Will Supernus Pharmaceuticals Inc. stock deliver long term returnsEarnings Performance Report & Verified Swing Trading Watchlist - Улправда
Why retail investors pile into Supernus Pharmaceuticals Inc. stockJuly 2025 Drop Watch & Technical Buy Zone Confirmation - Улправда
Is Supernus Pharmaceuticals (SUPN) Still Attractive After Strong Multi‑Year Share Price Gains - Yahoo Finance
Investment Recap: How Supernus Pharmaceuticals Inc stock compares to growth peersProduct Launch & Weekly High Momentum Picks - Bộ Nội Vụ
Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Unlocking a 24% Potential Upside in the CNS Market - DirectorsTalk Interviews
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade - MSN
(SUPN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Supernus Pharmaceuticals Earnings Notes - Trefis
Supernus projects $600M-$630M revenue for 2025 with robust growth in core products - MSN
Rice Hall James & Associates LLC Has $22.75 Million Position in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
SUPN (Supernus Pharmaceuticals) EV-to-OCF : 37.98 (As of Dec. 25, 2025) - GuruFocus
How Supernus Pharmaceuticals Inc. (SUPN) Affects Rotational Strategy Timing - Stock Traders Daily
Supernus Pharmaceuticals Insider Sold Shares Worth $1,008,150, According to a Recent SEC Filing - marketscreener.com
Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) SVP Sells 20,000 Shares of Stock - MarketBeat
Supernus Pharmaceuticals Senior VP Sells Shares - TradingView — Track All Markets
Supernus Pharmaceuticals (SUPN) Is Up 6.0% After FDA Approval Of ONAPGO Parkinson’s DrugHas The Bull Case Changed? - Sahm
Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order - Stocktwits
Stifel raises Supernus Pharmaceuticals stock price target to $55 from $50 - Investing.com Canada
Strong Results Lifted Supernus Pharmaceuticals (SUPN) in Q3 - Finviz
Why The OLB Group, Inc. stock attracts strong analyst attention - DonanımHaber
How risky is Supernus Pharmaceuticals Inc. stock nowJuly 2025 Outlook & Fast Gaining Stock Strategy Reports - Улправда
Is Supernus Pharmaceuticals Inc. stock overvalued by current metrics2025 Market Outlook & AI Driven Price Predictions - Улправда
Has the Market Fully Recognized Supernus Pharmaceuticals’ Strong Run and Growth Prospects in 2025? - Yahoo Finance
Supernus Pharmaceuticals (SUPN): Assessing Valuation After a 33% One-Year Return and Undervalued Narrative - Yahoo Finance
SUPN to Participate in Cantor Fitzgerald Virtual Meeting - GuruFocus
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back - Yahoo Finance
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back - The Motley Fool
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - MSN
Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue? - MSN
(SUPN) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Supernus Pharmaceuticals Reports Strong Q3 2025 Growth - MSN
Supernus Pharmaceuticals Says Postpartum Depression Treatment Receives Authorization From Health Canada - marketscreener.com
Can Supernus Pharmaceuticals Inc. stock resist market sell offsRate Hike & Scalable Portfolio Growth Ideas - Newser
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Popularity With Investors Is Under Threat From Overpricing - 富途牛牛
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics ... - Enidnews.com
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference - GlobeNewswire
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts - Yahoo! Finance Canada
Supernus Pharmaceuticals Inc (SUPN) 財務データ
収益
当期純利益
現金流量
EPS
Supernus Pharmaceuticals Inc (SUPN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mottola Frank | SVP, Chief Tech. Ops. Officer |
Dec 19 '25 |
Option Exercise |
28.82 |
20,000 |
576,500 |
30,496 |
| Mottola Frank | SVP, Chief Tech. Ops. Officer |
Dec 19 '25 |
Sale |
50.41 |
20,000 |
1,008,150 |
15,496 |
3.40%
大文字化:
|
ボリューム (24 時間):